Obatala Sciences Expands Biotech Hub in Charleston

The company is relocating to Blue Sky Labs to scale organ-on-a-chip testing models following new federal testing mandates.

Updated on Oct. 26, 2026 in Biotech

A close-up of a clear microfluidic chip on a white surface, representing modern human-cell testing technology. — Obatala Sciences is expanding its biotech operations at Charleston's Blue Sky Labs to scale human-cell-derived drug testing models following new federal testing mandates. AI Illustration. Upload story photo >

Live Poll

Should medical research prioritize human-cell testing over animal models to better represent diverse patient populations?

Obatala Sciences is relocating its operations to the Blue Sky Labs at the Medical University of South Carolina to scale its human-cell-derived drug testing technology. This move follows federal legislative shifts supporting a transition away from traditional animal-based testing methods.

Why it matters

The relocation accelerates the adoption of human-derived testing models in drug research, aligning with federal mandates for more relevant, non-animal methodologies. By centralizing operations in Charleston, the company aims to scale its biobank to address clinical testing gaps.

The company maintains a biobank of 10,000 human cell samples collected from approximately 1,000 donors. Notably, 80 percent of these samples are derived from women, providing a dataset for research on sex-specific drug responses.

The players

Obatala Sciences

A biotechnology firm specializing in human-cell-derived organ-on-a-chip models for drug discovery and clinical testing.

Medical University of South Carolina

A research institution hosting the Blue Sky Labs incubator program for emerging life science ventures.

South Carolina Department of Commerce

The state agency responsible for implementing economic development frameworks and recruiting high-growth technology companies.

The details

Obatala Sciences utilizes organ-on-a-chip testing devices, which are microfluidic systems that mimic the physiological functions of human organs using living human cells. These platforms are designed to replace animal models in pharmaceutical research by providing more accurate human-relevant data. The company is currently moving into renovated lab space at the Medical University of South Carolina to expand this capability.

October 2026: Obatala Sciences announces its move to the Medical University of South Carolina.
Over the next 12 months: The company plans to complete its relocation to Charleston.

The Tech Race

This move directly follows the passage of the FDA Modernization Act 3.0 by both the U.S. House and Senate, which creates a federal tailwind for non-animal testing alternatives. Obatala Sciences is positioning its facility to capitalize on this legislative mandate to replace traditional drug-screening paradigms.

While not directly impacting clinical patients today, the expansion aims to increase the accuracy of drug research and toxicity testing over the coming year. Stakeholders in the Charleston life sciences ecosystem should watch for the company's planned 10-fold increase in operational capacity.

The takeaway

Obatala Sciences is scaling its human-cell-testing capacity to meet a federal transition toward human-relevant research models. Readers can monitor the progress of the company's 10-fold expansion over the next 12 months to gauge the real-world uptake of organ-on-a-chip technologies.